{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:17:25Z","timestamp":1788135445291,"version":"build-2803163510"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":111,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["PC201317"],"award-info":[{"award-number":["PC201317"]}],"id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-72844-4","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:05:21Z","timestamp":1778601921000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["E-cadherin inactivation shapes tumor microenvironment specificities in invasive lobular breast cancer"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5007-2964","authenticated-orcid":false,"given":"Lounes","family":"Djerroudi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Mhaidly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2722-3071","authenticated-orcid":false,"given":"Yann","family":"Kieffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Damei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Croizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vithuzane","family":"Selvarasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7558-8705","authenticated-orcid":false,"given":"Geraldine","family":"Gentric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1755-6307","authenticated-orcid":false,"given":"Laetitia","family":"Fuhrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martial","family":"Caly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Richardot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8737-6817","authenticated-orcid":false,"given":"Renaud","family":"Leclere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enora","family":"Laas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9235-9816","authenticated-orcid":false,"given":"Caroline","family":"Malhaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-1961","authenticated-orcid":false,"given":"Julia M.","family":"Houthuijzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim","family":"Kloosterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9264-9792","authenticated-orcid":false,"given":"Jos","family":"Jonkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Benoist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Renault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5932-8949","authenticated-orcid":false,"given":"Fran\u00e7ois-Cl\u00e9ment","family":"Bidard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5754-5771","authenticated-orcid":false,"given":"Anne","family":"Vincent-Salomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3751-6989","authenticated-orcid":false,"given":"Fatima","family":"Mechta-Grigoriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"72844_CR1","unstructured":"Board WHOCoTE. Breast Tumours (2019)."},{"key":"72844_CR2","doi-asserted-by":"crossref","unstructured":"Berx, G. et al. E-cadherin is a tumour\/invasion suppressor gene mutated in human lobular breast cancers. EMBO J. 14, 6107\u20136115 (1995).","DOI":"10.1002\/j.1460-2075.1995.tb00301.x"},{"key":"72844_CR3","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.3390\/cancers13153695","volume":"13","author":"M Christgen","year":"2021","unstructured":"Christgen, M. et al. Lobular breast cancer: histomorphology and different concepts of a special spectrum of tumors. Cancers 13, 3695 (2021).","journal-title":"Cancers"},{"key":"72844_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/(SICI)1097-0142(19960101)77:1<113::AID-CNCR19>3.0.CO;2-8","volume":"77","author":"X Sastre-Garau","year":"1996","unstructured":"Sastre-Garau, X. et al. Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 77, 113\u2013120 (1996).","journal-title":"Cancer"},{"key":"72844_CR5","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ejca.2003.08.007","volume":"40","author":"S Ferlicot","year":"2004","unstructured":"Ferlicot, S. et al. Wide metastatic spreading in infiltrating lobular carcinoma of the breast. Eur. J. Cancer 40, 336\u2013341 (2004).","journal-title":"Eur. J. Cancer"},{"key":"72844_CR6","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1200\/JCO.2007.14.9336","volume":"26","author":"BC Pestalozzi","year":"2008","unstructured":"Pestalozzi, B. C. et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 international breast cancer study group clinical trials. JCO 26, 3006\u20133014 (2008).","journal-title":"JCO"},{"key":"72844_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejca.2007.10.009","volume":"44","author":"EA Rakha","year":"2008","unstructured":"Rakha, E. A. et al. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur. J. Cancer 44, 73\u201383 (2008).","journal-title":"Eur. J. Cancer"},{"key":"72844_CR8","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/jnci\/djac157","volume":"114","author":"S Oesterreich","year":"2022","unstructured":"Oesterreich, S. et al. Clinicopathological features and outcomes comparing patients with invasive ductal and lobular breast cancer. J. Natl. Cancer Inst. 114, 1511\u20131522 (2022).","journal-title":"J. Natl. Cancer Inst."},{"key":"72844_CR9","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1093\/jnci\/djx268","volume":"110","author":"C Desmedt","year":"2018","unstructured":"Desmedt, C. et al. Immune infiltration in invasive lobular breast cancer. J. Natl. Cancer Inst. 110, 768\u2013776 (2018).","journal-title":"J. Natl. Cancer Inst."},{"key":"72844_CR10","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1038\/s41379-020-0561-9","volume":"33","author":"J-C Tille","year":"2020","unstructured":"Tille, J.-C. et al. Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma. Mod. Pathol. 33, 2198\u20132207 (2020).","journal-title":"Mod. Pathol."},{"key":"72844_CR11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","volume":"33","author":"A Costa","year":"2018","unstructured":"Costa, A. et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell 33, 463\u2013479 (2018).","journal-title":"Cancer Cell"},{"key":"72844_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-14134-w","volume":"11","author":"F Pelon","year":"2020","unstructured":"Pelon, F. et al. Cancer-associated fibroblast heterogeneity in axillary lymph nodes drives metastases in breast cancer through complementary mechanisms. Nat. Commun. 11, 1\u201320 (2020).","journal-title":"Nat. Commun."},{"key":"72844_CR13","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai, E. et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat. Rev. Cancer 20, 174\u2013186 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"72844_CR14","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/imr.12978","volume":"302","author":"R Mhaidly","year":"2021","unstructured":"Mhaidly, R. & Mechta-Grigoriou, F. Role of cancer-associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer. Immunol. Rev. 302, 259\u2013272 (2021).","journal-title":"Immunol. Rev."},{"key":"72844_CR15","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.semcancer.2022.04.008","volume":"86","author":"A Peltier","year":"2022","unstructured":"Peltier, A., Seban, R.-D., Buvat, I., Bidard, F.-C. & Mechta-Grigoriou, F. Fibroblast heterogeneity in solid tumors: From single cell analysis to whole-body imaging. Semin. Cancer Biol. 86, 262\u2013272 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"72844_CR16","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.cell.2023.03.016","volume":"186","author":"Y Chhabra","year":"2023","unstructured":"Chhabra, Y. & Weeraratna, A. T. Fibroblasts in cancer: Unity in heterogeneity. Cell 186, 1580\u20131609 (2023).","journal-title":"Cell"},{"key":"72844_CR17","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.20162024","volume":"214","author":"D \u00d6hlund","year":"2017","unstructured":"\u00d6hlund, D. et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J. Exp. Med. 214, 579\u2013596 (2017).","journal-title":"J. Exp. Med."},{"key":"72844_CR18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1152\/physrev.00048.2019","volume":"101","author":"G Biffi","year":"2021","unstructured":"Biffi, G. & Tuveson, D. A. Diversity and biology of cancer-associated fibroblasts. Physiol. Rev. 101, 147\u2013176 (2021).","journal-title":"Physiol. Rev."},{"key":"72844_CR19","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","volume":"9","author":"E Elyada","year":"2019","unstructured":"Elyada, E. et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 9, 1102\u20131123 (2019).","journal-title":"Cancer Discov."},{"key":"72844_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/path.5224","volume":"248","author":"C Neuzillet","year":"2019","unstructured":"Neuzillet, C. et al. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma. J. Pathol. 248, 51\u201365 (2019).","journal-title":"J. Pathol."},{"key":"72844_CR21","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1158\/2159-8290.CD-19-0644","volume":"10","author":"CX Dominguez","year":"2020","unstructured":"Dominguez, C. X. et al. Single-cell RNA sequencing reveals stromal evolution into LRRC15+ myofibroblasts as a determinant of patient response to cancer immunotherapy. Cancer Discov. 10, 232\u2013253 (2020).","journal-title":"Cancer Discov."},{"key":"72844_CR22","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/ng.3818","volume":"49","author":"H Li","year":"2017","unstructured":"Li, H. et al. Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors. Nat. Genet. 49, 708\u2013718 (2017).","journal-title":"Nat. Genet."},{"key":"72844_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-03348-z","volume":"9","author":"A-M Givel","year":"2018","unstructured":"Givel, A.-M. et al. miR200-regulated CXCL12\u03b2 promotes fibroblast heterogeneity and immunosuppression in ovarian cancers. Nat. Commun. 9, 1\u201320 (2018).","journal-title":"Nat. Commun."},{"key":"72844_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-07582-3","volume":"9","author":"M Bartoschek","year":"2018","unstructured":"Bartoschek, M. et al. Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nat. Commun. 9, 1\u201313 (2018).","journal-title":"Nat. Commun."},{"key":"72844_CR25","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1158\/2326-6066.CIR-18-0098","volume":"6","author":"V Cremasco","year":"2018","unstructured":"Cremasco, V. et al. FAP Delineates heterogeneous and functionally divergent stromal cells in immune-excluded breast tumors. Cancer Immunol. Res. 6, 1472\u20131485 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"72844_CR26","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/s43018-020-0082-y","volume":"1","author":"G Friedman","year":"2020","unstructured":"Friedman, G. et al. Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4+ and PDPN+ CAFs to clinical outcome. Nat. Cancer 1, 692\u2013708 (2020).","journal-title":"Nat. Cancer"},{"key":"72844_CR27","doi-asserted-by":"crossref","unstructured":"Kieffer, Y. et al. Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discov. 10, 1330\u20131351 (2020).","DOI":"10.1158\/2159-8290.CD-19-1384"},{"key":"72844_CR28","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.3390\/cancers12051307","volume":"12","author":"A Sebastian","year":"2020","unstructured":"Sebastian, A. et al. Single-cell transcriptomic analysis of tumor-derived fibroblasts and normal tissue-resident fibroblasts reveals fibroblast heterogeneity in breast cancer. Cancers 12, 1307 (2020).","journal-title":"Cancers"},{"key":"72844_CR29","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","volume":"53","author":"SZ Wu","year":"2021","unstructured":"Wu, S. Z. et al. A single-cell and spatially resolved atlas of human breast cancers. Nat. Genet. 53, 1334\u20131347 (2021).","journal-title":"Nat. Genet."},{"key":"72844_CR30","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.ccell.2022.09.015","volume":"40","author":"DS Foster","year":"2022","unstructured":"Foster, D. S. et al. Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin. Cancer Cell 40, 1392\u20131406 (2022).","journal-title":"Cancer Cell"},{"key":"72844_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01311-9","volume":"22","author":"C Bonneau","year":"2020","unstructured":"Bonneau, C. et al. A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer. Breast Cancer Res. 22, 76 (2020).","journal-title":"Breast Cancer Res."},{"key":"72844_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44886-z","volume":"15","author":"C Cohen","year":"2024","unstructured":"Cohen, C. et al. WNT-dependent interaction between inflammatory fibroblasts and FOLR2+ macrophages promotes fibrosis in chronic kidney disease. Nat. Commun. 15, 743 (2024).","journal-title":"Nat. Commun."},{"key":"72844_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47068-z","volume":"15","author":"H Croizer","year":"2024","unstructured":"Croizer, H. et al. Deciphering the spatial landscape and plasticity of immunosuppressive fibroblasts in breast cancer. Nat. Commun. 15, 2806 (2024).","journal-title":"Nat. Commun."},{"key":"72844_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45595-3","volume":"15","author":"M Licaj","year":"2024","unstructured":"Licaj, M. et al. Residual ANTXR1+ myofibroblasts after chemotherapy inhibit anti-tumor immunity via YAP1 signaling pathway. Nat. Commun. 15, 1312 (2024).","journal-title":"Nat. Commun."},{"key":"72844_CR35","doi-asserted-by":"publisher","first-page":"12139","DOI":"10.1073\/pnas.1412910111","volume":"111","author":"AE Denton","year":"2014","unstructured":"Denton, A. E., Roberts, E. W., Linterman, M. A. & Fearon, D. T. Fibroblastic reticular cells of the lymph node are required for retention of resting but not activated CD8+ T cells. Proc. Natl. Acad. Sci. USA. 111, 12139\u201312144 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"72844_CR36","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00262-015-1742-0","volume":"64","author":"H Takahashi","year":"2015","unstructured":"Takahashi, H. et al. Immunosuppressive activity of cancer-associated fibroblasts in head and neck squamous cell carcinoma. Cancer Immunol. Immunother. 64, 1407\u20131417 (2015).","journal-title":"Cancer Immunol. Immunother."},{"key":"72844_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11762","volume":"7","author":"MK Ruhland","year":"2016","unstructured":"Ruhland, M. K. et al. Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. Nat. Commun. 7, 11762 (2016).","journal-title":"Nat. Commun."},{"key":"72844_CR38","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1158\/0008-5472.CAN-15-2973","volume":"76","author":"X Yang","year":"2016","unstructured":"Yang, X. et al. FAP Promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling. Cancer Res. 76, 4124\u20134135 (2016).","journal-title":"Cancer Res."},{"key":"72844_CR39","doi-asserted-by":"publisher","first-page":"23282","DOI":"10.18632\/oncotarget.7818","volume":"7","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y. & Ertl, H. C. J. Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+T cells within tumors. Oncotarget 7, 23282\u201323299 (2016).","journal-title":"Oncotarget"},{"key":"72844_CR40","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1038\/onc.2017.65","volume":"36","author":"N Cohen","year":"2017","unstructured":"Cohen, N. et al. Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1. Oncogene 36, 4457\u20134468 (2017).","journal-title":"Oncogene"},{"key":"72844_CR41","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2019104063","volume":"39","author":"SZ Wu","year":"2020","unstructured":"Wu, S. Z. et al. Stromal cell diversity associated with immune evasion in human triple-negative breast cancer. EMBO J. 39, e104063 (2020).","journal-title":"EMBO J."},{"key":"72844_CR42","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.3390\/cancers13235878","volume":"13","author":"I Magagna","year":"2021","unstructured":"Magagna, I. et al. CD73-Mediated immunosuppression is linked to a specific fibroblast population that paves the way for new therapy in breast cancer. Cancers 13, 5878 (2021).","journal-title":"Cancers"},{"key":"72844_CR43","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.3390\/cancers12092687","volume":"12","author":"P Freeman","year":"2020","unstructured":"Freeman, P. & Mielgo, A. Cancer-associated fibroblast mediated inhibition of CD8+cytotoxic T cell accumulation in tumours: mechanisms and therapeutic opportunities. Cancers 12, 2687 (2020).","journal-title":"Cancers"},{"key":"72844_CR44","doi-asserted-by":"publisher","first-page":"310","DOI":"10.4049\/jimmunol.2001203","volume":"206","author":"AT Baker","year":"2021","unstructured":"Baker, A. T., Abuwarwar, M. H., Poly, L., Wilkins, S. & Fletcher, A. L. Cancer-associated fibroblasts and T cells: from mechanisms to outcomes. J. Immunol. 206, 310\u2013320 (2021).","journal-title":"J. Immunol."},{"key":"72844_CR45","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.3390\/cancers13122995","volume":"13","author":"L Gorchs","year":"2021","unstructured":"Gorchs, L. & Kaipe, H. Interactions between cancer-associated fibroblasts and T cells in the pancreatic tumor microenvironment and the role of chemokines. Cancers 13, 2995 (2021).","journal-title":"Cancers"},{"key":"72844_CR46","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/2159-8290.CD-18-0710","volume":"9","author":"G Biffi","year":"2019","unstructured":"Biffi, G. et al. IL1-Induced JAK\/STAT signaling Is antagonized by TGF\u03b2 to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 9, 282\u2013301 (2019).","journal-title":"Cancer Discov."},{"key":"72844_CR47","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.ccell.2021.10.009","volume":"39","author":"AM Leader","year":"2021","unstructured":"Leader, A. M. et al. Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification. Cancer Cell 39, 1594\u20131609 (2021).","journal-title":"Cancer Cell"},{"key":"72844_CR48","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10549-015-3668-9","volume":"155","author":"S Nakagawa","year":"2016","unstructured":"Nakagawa, S. et al. Tumor microenvironment in invasive lobular carcinoma: possible therapeutic targets. Breast Cancer Res. Treat. 155, 65\u201375 (2016).","journal-title":"Breast Cancer Res. Treat."},{"key":"72844_CR49","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10549-016-3929-2","volume":"159","author":"CK Park","year":"2016","unstructured":"Park, C. K., Jung, W. H. & Koo, J. S. Expression of cancer-associated fibroblast-related proteins differs between invasive lobular carcinoma and invasive ductal carcinoma. Breast Cancer Res. Treat. 159, 55\u201369 (2016).","journal-title":"Breast Cancer Res. Treat."},{"key":"72844_CR50","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41591-021-01323-8","volume":"27","author":"A Bassez","year":"2021","unstructured":"Bassez, A. et al. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nat. Med. 27, 820\u2013832 (2021).","journal-title":"Nat. Med."},{"key":"72844_CR51","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020107333","volume":"40","author":"B Pal","year":"2021","unstructured":"Pal, B. et al. A single-cell RNA expression atlas of normal, preneoplastic and tumorigenic states in the human breast. EMBO J. 40, e107333 (2021).","journal-title":"EMBO J."},{"key":"72844_CR52","doi-asserted-by":"crossref","unstructured":"Hofer, I. et al. An extracellular matrix-producing subset of cancer-associated fibroblasts drives chemoresistance in breast cancer via SRC activation and G0S2 upregulation. Cancer Res. 86, 1054\u20131072 (2025).","DOI":"10.1158\/0008-5472.CAN-25-0966"},{"key":"72844_CR53","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1200\/JCO.2010.30.5037","volume":"29","author":"SM Mahmoud","year":"2011","unstructured":"Mahmoud, S. M. et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J. Clin. Oncol. 29, 1949\u20131955 (2011).","journal-title":"J. Clin. Oncol."},{"key":"72844_CR54","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/annonc\/mdu191","volume":"25","author":"HR Ali","year":"2014","unstructured":"Ali, H. R. et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann. Oncol. 25, 1536\u20131543 (2014).","journal-title":"Ann. Oncol."},{"key":"72844_CR55","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/s41591-018-0078-7","volume":"24","author":"P Savas","year":"2018","unstructured":"Savas, P. et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat. Med. 24, 986\u2013993 (2018).","journal-title":"Nat. Med."},{"key":"72844_CR56","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s43018-023-00527-w","volume":"4","author":"S Onkar","year":"2023","unstructured":"Onkar, S. et al. Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment. Nat. Cancer 4, 516\u2013534 (2023).","journal-title":"Nat. Cancer"},{"key":"72844_CR57","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd5778","volume":"6","author":"P Gueguen","year":"2021","unstructured":"Gueguen, P. et al. Contribution of resident and circulating precursors to tumor-infiltrating CD8+ T cell populations in lung cancer. Sci. Immunol 6, eabd5778 (2021).","journal-title":"Sci. Immunol"},{"key":"72844_CR58","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40425-018-0399-6","volume":"6","author":"F Mami-Chouaib","year":"2018","unstructured":"Mami-Chouaib, F. et al. Resident memory T cells, critical components in tumor immunology. J. Immunother. Cancer 6, 87 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"72844_CR59","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1158\/1078-0432.CCR-17-2257","volume":"24","author":"J Edwards","year":"2018","unstructured":"Edwards, J. et al. CD103+ Tumor-resident CD8+ T cells are associated with improved survival in immunotherapy-na\u00efve melanoma patients and expand significantly during Anti-PD-1 treatment. Clin. Cancer Res. 24, 3036\u20133045 (2018).","journal-title":"Clin. Cancer Res."},{"key":"72844_CR60","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41571-020-0333-y","volume":"17","author":"A Byrne","year":"2020","unstructured":"Byrne, A. et al. Tissue-resident memory T cells in breast cancer control and immunotherapy responses. Nat. Rev. Clin. Oncol. 17, 341\u2013348 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"72844_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100127","volume":"1","author":"S Corgnac","year":"2020","unstructured":"Corgnac, S. et al. CD103+CD8+ TRM cells accumulate in tumors of anti-PD-1-responder lung cancer patients and are tumor-reactive lymphocytes enriched with Tc17. Cell Rep. Med. 1, 100127 (2020).","journal-title":"Cell Rep. Med."},{"key":"72844_CR62","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.ccell.2023.01.004","volume":"41","author":"B Virassamy","year":"2023","unstructured":"Virassamy, B. et al. Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer. Cancer Cell 41, 585\u2013601 (2023).","journal-title":"Cancer Cell"},{"key":"72844_CR63","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1158\/0008-5472.CAN-18-1722","volume":"79","author":"BD Shields","year":"2019","unstructured":"Shields, B. D. et al. Loss of E-cadherin inhibits CD103 antitumor activity and reduces checkpoint blockade responsiveness in melanoma. Cancer Res. 79, 1113\u20131123 (2019).","journal-title":"Cancer Res."},{"key":"72844_CR64","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/ni.2745","volume":"14","author":"CN Skon","year":"2013","unstructured":"Skon, C. N. et al. Transcriptional downregulation of S1pr1 is required for the establishment of resident memory CD8+ T cells. Nat. Immunol. 14, 1285\u20131293 (2013).","journal-title":"Nat. Immunol."},{"key":"72844_CR65","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S0959-8049(02)00633-0","volume":"39","author":"E Quinn","year":"2003","unstructured":"Quinn, E., Hawkins, N., Yip, Y. L., Suter, C. & Ward, R. CD103+ intraepithelial lymphocytes\u2013a unique population in microsatellite unstable sporadic colorectal cancer. Eur. J. Cancer 39, 469\u2013475 (2003).","journal-title":"Eur. J. Cancer"},{"key":"72844_CR66","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1158\/1078-0432.CCR-13-1877","volume":"20","author":"JR Webb","year":"2014","unstructured":"Webb, J. R., Milne, K., Watson, P., Deleeuw, R. J. & Nelson, B. H. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin. Cancer Res. 20, 434\u2013444 (2014).","journal-title":"Clin. Cancer Res."},{"key":"72844_CR67","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.4049\/jimmunol.1402711","volume":"194","author":"F Djenidi","year":"2015","unstructured":"Djenidi, F. et al. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J. Immunol. 194, 3475\u20133486 (2015).","journal-title":"J. Immunol."},{"key":"72844_CR68","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.juro.2015.02.2941","volume":"194","author":"B Wang","year":"2015","unstructured":"Wang, B. et al. CD103+ Tumor infiltrating lymphocytes predict a favorable prognosis in urothelial cell carcinoma of the bladder. J. Urol. 194, 556\u2013562 (2015).","journal-title":"J. Urol."},{"key":"72844_CR69","doi-asserted-by":"publisher","first-page":"6290","DOI":"10.1158\/1078-0432.CCR-16-0732","volume":"22","author":"Z-Q Wang","year":"2016","unstructured":"Wang, Z.-Q. et al. CD103 and Intratumoral immune response in breast cancer. Clin. Cancer Res. 22, 6290\u20136297 (2016).","journal-title":"Clin. Cancer Res."},{"key":"72844_CR70","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1158\/2159-8290.CD-21-0683","volume":"12","author":"V Kumar","year":"2022","unstructured":"Kumar, V. et al. Single-cell atlas of lineage states, tumor microenvironment, and subtype-specific expression programs in gastric cancer. Cancer Discov. 12, 670\u2013691 (2022).","journal-title":"Cancer Discov."},{"key":"72844_CR71","doi-asserted-by":"crossref","unstructured":"Van Baelen, K. et al. Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer. Ann. Oncol. 33, 769\u2013785 (2022).","DOI":"10.1016\/j.annonc.2022.05.006"},{"key":"72844_CR72","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nm1764","volume":"14","author":"G Finak","year":"2008","unstructured":"Finak, G. et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14, 518\u2013527 (2008).","journal-title":"Nat. Med."},{"key":"72844_CR73","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S0945-053X(02)00037-9","volume":"21","author":"JD Whittard","year":"2002","unstructured":"Whittard, J. D. et al. E-cadherin is a ligand for integrin alpha2beta1. Matrix Biol. 21, 525\u2013532 (2002).","journal-title":"Matrix Biol."},{"key":"72844_CR74","doi-asserted-by":"publisher","first-page":"31157","DOI":"10.1073\/pnas.2010209117","volume":"117","author":"O Shafraz","year":"2020","unstructured":"Shafraz, O., Xie, B., Yamada, S. & Sivasankar, S. Mapping transmembrane binding partners for E-cadherin ectodomains. Proc. Natl. Acad. Sci. USA. 117, 31157\u201331165 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"72844_CR75","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1242\/jcs.035246","volume":"122","author":"P Aluwihare","year":"2009","unstructured":"Aluwihare, P. et al. Mice that lack activity of alphavbeta6- and alphavbeta8-integrins reproduce the abnormalities of Tgfb1- and Tgfb3-null mice. J. Cell Sci. 122, 227\u2013232 (2009).","journal-title":"J. Cell Sci."},{"key":"72844_CR76","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature10152","volume":"474","author":"M Shi","year":"2011","unstructured":"Shi, M. et al. Latent TGF-\u03b2 structure and activation. Nature 474, 343\u2013349 (2011).","journal-title":"Nature"},{"key":"72844_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01070-3","volume":"7","author":"M Zhao","year":"2022","unstructured":"Zhao, M. et al. Targeting fibrosis: mechanisms and clinical trials. Sig. Transduct. Target. Ther. 7, 1\u201321 (2022).","journal-title":"Sig. Transduct. Target. Ther."},{"key":"72844_CR78","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1006\/excr.2000.4869","volume":"257","author":"MB Vaughan","year":"2000","unstructured":"Vaughan, M. B., Howard, E. W. & Tomasek, J. J. Transforming growth factor-\u03b21 promotes the morphological and functional differentiation of the myofibroblast. Exp. Cell Res. 257, 180\u2013189 (2000).","journal-title":"Exp. Cell Res."},{"key":"72844_CR79","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ccr.2012.08.013","volume":"22","author":"A Calon","year":"2012","unstructured":"Calon, A. et al. Dependency of colorectal cancer on a TGF-\u03b2-driven program in stromal cells for metastasis initiation. Cancer Cell 22, 571\u2013584 (2012).","journal-title":"Cancer Cell"},{"key":"72844_CR80","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41586-022-05272-1","volume":"611","author":"AT Krishnamurty","year":"2022","unstructured":"Krishnamurty, A. T. et al. LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity. Nature 611, 148\u2013154 (2022).","journal-title":"Nature"},{"key":"72844_CR81","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41577-021-00540-z","volume":"21","author":"S Davidson","year":"2021","unstructured":"Davidson, S. et al. Fibroblasts as immune regulators in infection, inflammation and cancer. Nat. Rev. Immunol. 21, 704\u2013717 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"72844_CR82","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ccell.2023.02.015","volume":"41","author":"G Caligiuri","year":"2023","unstructured":"Caligiuri, G. & Tuveson, D. A. Activated fibroblasts in cancer: Perspectives and challenges. Cancer Cell 41, 434\u2013449 (2023).","journal-title":"Cancer Cell"},{"key":"72844_CR83","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1172\/JCI45817","volume":"122","author":"H Salmon","year":"2012","unstructured":"Salmon, H. et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J. Clin. Invest. 122, 899\u2013910 (2012).","journal-title":"J. Clin. Invest."},{"key":"72844_CR84","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"72844_CR85","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.58688","volume":"10","author":"A Nicolas-Boluda","year":"2021","unstructured":"Nicolas-Boluda, A. et al. Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment. ELife 10, e58688 (2021).","journal-title":"ELife"},{"key":"72844_CR86","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov, H., Orhan, A., Christensen, J. P. & G\u00f6genur, I. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Br. J. Cancer 124, 359\u2013367 (2021).","journal-title":"Br. J. Cancer"},{"key":"72844_CR87","doi-asserted-by":"crossref","unstructured":"Heindl, A. et al. Relevance of spatial heterogeneity of immune infiltration for predicting risk of recurrence after endocrine therapy of ER\u2009+ breast cancer. J. Natl. Cancer Inst. 110, 166\u2013175 (2018).","DOI":"10.1093\/jnci\/djx137"},{"key":"72844_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07654-y","volume":"20","author":"Z-H Gao","year":"2020","unstructured":"Gao, Z.-H., Li, C.-X., Liu, M. & Jiang, J.-Y. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis. BMC Cancer 20, 1150 (2020).","journal-title":"BMC Cancer"},{"key":"72844_CR89","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.153963","volume":"7","author":"CA Egelston","year":"2022","unstructured":"Egelston, C. A. et al. Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor-positive breast cancer. JCI Insight 7, e153963 (2022).","journal-title":"JCI Insight"},{"key":"72844_CR90","doi-asserted-by":"crossref","unstructured":"Makhlouf, S. et al. Evaluation of tumour infiltrating lymphocytes in luminal breast cancer using artificial intelligence. Br. J. Cancer 129, 1747\u20131758 (2023).","DOI":"10.1038\/s41416-023-02451-3"},{"key":"72844_CR91","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-12-1000","volume":"19","author":"AK Dunbier","year":"2013","unstructured":"Dunbier, A. K. et al. Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance. Clin. Cancer Res. 19, 2775\u20132786 (2013).","journal-title":"Clin. Cancer Res."},{"key":"72844_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01285-8","volume":"22","author":"SK Skriver","year":"2020","unstructured":"Skriver, S. K., Jensen, M.-B., Knoop, A. S., Ejlertsen, B. & Laenkholm, A.-V. Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial. Breast Cancer Res. 22, 46 (2020).","journal-title":"Breast Cancer Res."},{"key":"72844_CR93","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3390\/ijms19020611","volume":"19","author":"NJ Rothenberger","year":"2018","unstructured":"Rothenberger, N. J., Somasundaram, A. & Stabile, L. P. The role of the estrogen pathway in the tumor microenvironment. Int. J. Mol. Sci. 19, 611 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"72844_CR94","doi-asserted-by":"publisher","first-page":"15048","DOI":"10.3390\/ijms242015048","volume":"24","author":"A Moisand","year":"2023","unstructured":"Moisand, A. et al. Hormone Receptor Signaling and Breast Cancer Resistance to Anti-Tumor Immunity. Int. J. Mol. Sci. 24, 15048 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"72844_CR95","doi-asserted-by":"crossref","unstructured":"Li, Y. et al. Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy. J. Immunother. Cancer 12, e009934 (2024).","DOI":"10.1136\/jitc-2024-009934"},{"key":"72844_CR96","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/sj.bjc.6604741","volume":"99","author":"R Torrisi","year":"2008","unstructured":"Torrisi, R. et al. Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and\/or PgR-positive breast cancer: clinical and biological activity. Br. J. Cancer 99, 1564\u20131571 (2008).","journal-title":"Br. J. Cancer"},{"key":"72844_CR97","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1200\/JCO.2015.66.1595","volume":"34","author":"MN Dickler","year":"2016","unstructured":"Dickler, M. N. et al. Phase III trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer: CALGB 40503 (Alliance). J. Clin. Oncol. 34, 2602\u20132609 (2016).","journal-title":"J. Clin. Oncol."},{"key":"72844_CR98","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s43018-023-00542-x","volume":"4","author":"L Voorwerk","year":"2023","unstructured":"Voorwerk, L. et al. PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial. Nat. Cancer 4, 535\u2013549 (2023).","journal-title":"Nat. Cancer"},{"key":"72844_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100463","volume":"37","author":"L Djerroudi","year":"2024","unstructured":"Djerroudi, L. et al. Molecular and clinical portrait of HER2-low pnvasive lobular carcinomas. Mod. Pathol. 37, 100463 (2024).","journal-title":"Mod. Pathol."},{"key":"72844_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100570","volume":"37","author":"L Djerroudi","year":"2024","unstructured":"Djerroudi, L. et al. E-Cadherin mutational landscape and outcomes in breast invasive lobular carcinoma. Mod. Pathol. 37, 100570 (2024).","journal-title":"Mod. Pathol."},{"key":"72844_CR101","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann. Oncol. 26, 259\u2013271 (2015).","journal-title":"Ann. Oncol."},{"key":"72844_CR102","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/PAP.0000000000000162","volume":"24","author":"S Hendry","year":"2017","unstructured":"Hendry, S. et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method From the international immunooncology biomarkers working group: part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. Adv. Anat. Pathol. 24, 235\u2013251 (2017).","journal-title":"Adv. Anat. Pathol."},{"key":"72844_CR103","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update. J. Clin. Oncol. 36, 2105\u20132122 (2018).","journal-title":"J. Clin. Oncol."},{"key":"72844_CR104","doi-asserted-by":"publisher","first-page":"545","DOI":"10.5858\/arpa.2019-0904-SA","volume":"144","author":"KH Allison","year":"2020","unstructured":"Allison, K. H. et al. Estrogen and progesterone receptor testing in breast cancer: American society of clinical oncology\/college of American pathologists guideline update. Arch. Pathol. Lab. Med. 144, 545\u2013563 (2020).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"72844_CR105","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.annpat.2021.07.014","volume":"41","author":"C Franchet","year":"2021","unstructured":"Franchet, C. et al. [2021 update of the GEFPICS\u2019 recommendations for HER2 status assessment in invasive breast cancer in France]. Ann. Pathol. 41, 507\u2013520 (2021).","journal-title":"Ann. Pathol."},{"key":"72844_CR106","first-page":"144","volume":"16","author":"AL Balaton","year":"1996","unstructured":"Balaton, A. L. et al. [Recommendations for the immunohistochemical evaluation of hormone receptors on paraffin sections of breast cancer. Study Group on Hormone Receptors using Immunohistochemistry FNCLCC\/AFAQAP. National Federation of Centres to Combat Cancer\/French Association for Quality Assurance in Pathology]. Ann. Pathol. 16, 144\u2013148 (1996).","journal-title":"Ann. Pathol."},{"key":"72844_CR107","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1046\/j.1365-2559.2000.01006.x","volume":"37","author":"B Zafrani","year":"2000","unstructured":"Zafrani, B. et al. High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Histopathology 37, 536\u2013545 (2000).","journal-title":"Histopathology"},{"key":"72844_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: Open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"72844_CR109","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s43018-022-00356-3","volume":"3","author":"T Chu","year":"2022","unstructured":"Chu, T., Wang, Z., Pe\u2019er, D. & Danko, C. G. Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology. Nat. Cancer 3, 505\u2013517 (2022).","journal-title":"Nat. Cancer"},{"key":"72844_CR110","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas N","year":"2012","unstructured":"Cancer Genome Atlas N Comprehensive molecular portraits of human breast tumours. Nature 490, 61\u201370 (2012).","journal-title":"Nature"},{"key":"72844_CR111","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/j.celrep.2016.07.059","volume":"16","author":"MC Boelens","year":"2016","unstructured":"Boelens, M. C. et al. PTEN Loss in E-Cadherin-deficient mouse mammary epithelial cells rescues apoptosis and results in development of classical invasive lobular carcinoma. Cell Rep. 16, 2087\u20132101 (2016).","journal-title":"Cell Rep."},{"key":"72844_CR112","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/emmm.201303297","volume":"6","author":"IJ Huijbers","year":"2014","unstructured":"Huijbers, I. J. et al. Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells. EMBO Mol. Med. 6, 212\u2013225 (2014).","journal-title":"EMBO Mol. Med."},{"key":"72844_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35793-w","volume":"14","author":"JM Houthuijzen","year":"2023","unstructured":"Houthuijzen, J. M. et al. CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast cancer. Nat. Commun. 14, 183 (2023).","journal-title":"Nat. Commun."},{"key":"72844_CR114","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773\u2013782 (2019).","journal-title":"Nat. Biotechnol."},{"key":"72844_CR115","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41586-019-1450-6","volume":"572","author":"MD Wellenstein","year":"2019","unstructured":"Wellenstein, M. D. et al. Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. Nature 572, 538\u2013542 (2019).","journal-title":"Nature"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72844-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72844-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72844-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:02:32Z","timestamp":1788134552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72844-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":115,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["72844"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-72844-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.M.-G. and A.V.-S received research support from Roche, Institut Roche and the MSD Foundation. L.D. received research mobility support from Institut Servier. F.-C.B. reports research funding from GE Healthcare, Menarini Silicon Biosystems, Merck KGaA, MSD, Natera, Novartis, Personalis, Pfizer, Prolynx, Roche, SAGADx and Tempus; has served on advisory boards for AstraZeneca, Carrick Therapeutics, Daiichi Sankyo, Hengrui, Inatherys, Lilly, Menarini Silicon Biosystems, Novartis, Pfizer, Relay Therapeutics, Roche and Tempus; and has received speaker honoraria and travel support from AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Pfizer and Roche. Other authors declare no potential competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9249"}}